Truist analyst Jailendra Singh lowered the firm’s price target on Iqvia to $244 from $265 but keeps a Buy rating on the shares after its Q1 earnings. The analyst notes that the company’s lower than expected results in the Technology & Analytics Solutions overshadowed the strong showing in the CRO business, though the stock has been relatively shielded compared to its CRO peers as a result of its advanced capabilities in tech and longitudinal data.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IQV:
